CRISPR/Cas9-Mediated Genome Editing of Herpesviruses Limits Productive and Latent Infections
暂无分享,去创建一个
Anita C. Schürch | Monique Nijhuis | E. Kruse | A. Schürch | E. Wiertz | R. Lebbink | M. Nijhuis | Marjolein J. G. Hooykaas | Ferdy R. van Diemen | P. V. van Ham | Carlijn E. Bruggeling | Elisabeth M. Kruse | Petra M. van Ham | Saskia M. Imhof | Emmanuel J. H. J. Wiertz | Robert Jan Lebbink | S. Imhof | C. Bruggeling | Marjolein J G Hooykaas
[1] J. Yates,et al. A vector that replicates as a plasmid and can be efficiently selected in B-lymphoblasts transformed by Epstein-Barr virus , 1985, Molecular and cellular biology.
[2] G. Hayward,et al. Sequence-specific DNA binding of the Epstein-Barr virus nuclear antigen (EBNA-1) to clustered sites in the plasmid maintenance region , 1985, Cell.
[3] D. Reisman,et al. A putative origin of replication of plasmids derived from Epstein-Barr virus is composed of two cis-acting components , 1985, Molecular and cellular biology.
[4] J. Yates,et al. Stable replication of plasmids derived from Epstein–Barr virus in various mammalian cells , 1985, Nature.
[5] C. M. Preston,et al. An in vitro latency system for herpes simplex virus type 2. , 1986, The Journal of general virology.
[6] D. Reisman,et al. trans activation of an Epstein-Barr viral transcriptional enhancer by the Epstein-Barr viral nuclear antigen 1 , 1986, Molecular and cellular biology.
[7] C. M. Preston,et al. Herpes simplex virus genes involved in latency in vitro. , 1987, The Journal of general virology.
[8] I. Lehman,et al. A DNA helicase induced by herpes simplex virus type 1. , 1988, Nucleic acids research.
[9] L. Melton,et al. Epidemiology of ocular herpes simplex. Incidence in Rochester, Minn, 1950 through 1982. , 1989, Archives of ophthalmology.
[10] I. Lehman,et al. Herpes simplex virus 1 helicase-primase: a complex of three herpes-encoded gene products. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[11] U. Nater,et al. Epstein-Barr virus. , 1991, The Journal of family practice.
[12] S. Takada,et al. Quantitative analysis of genomic polymorphism of herpes simplex virus type 1 strains from six countries: studies of molecular evolution and molecular epidemiology of the virus. , 1994, The Journal of general virology.
[13] R. Samulski,et al. Selective and rapid uptake of adeno-associated virus type 2 in brain. , 1998, Human gene therapy.
[14] L. Hutt-Fletcher,et al. Epstein-Barr Virus gH Is Essential for Penetration of B Cells but Also Plays a Role in Attachment of Virus to Epithelial Cells , 2000, Journal of Virology.
[15] J. Rajčáni,et al. Mechanisms of replication of alpha- and betaherpesviruses and their pathogenesis. , 2001, Bratislavske lekarske listy.
[16] E. Robertson,et al. OF KAPOSI ’ S SARCOMA-ASSOCIATED HERPESVIRUS , 2002 .
[17] T. Shenk,et al. Functional map of human cytomegalovirus AD169 defined by global mutational analysis , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[18] V. Štolc,et al. Functional profiling of a human cytomegalovirus genome , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[19] Martin Kühne,et al. A pathway of double-strand break rejoining dependent upon ATM, Artemis, and proteins locating to gamma-H2AX foci. , 2004, Molecular cell.
[20] A. Izeta,et al. Compartmentalization of VP16 in Cells Infected with Recombinant Herpes Simplex Virus Expressing VP16-Green Fluorescent Protein Fusion Proteins , 2004, Journal of Virology.
[21] S. Kenney,et al. Lytic Induction Therapy for Epstein-Barr Virus-Positive B-Cell Lymphomas , 2004, Journal of Virology.
[22] P. Sharp,et al. Cre-lox-regulated conditional RNA interference from transgenes. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[23] Y. Stierhof,et al. Human Cytomegalovirus Labeled with Green Fluorescent Protein for Live Analysis of Intracellular Particle Movements , 2005, Journal of Virology.
[24] J. Tolar,et al. A picornaviral 2A-like sequence-based tricistronic vector allowing for high-level therapeutic gene expression coupled to a dual-reporter system. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.
[25] H. Mizuguchi,et al. Eradication of Epstein-Barr virus episome and associated inhibition of infected tumor cell growth by adenovirus vector-mediated transduction of dominant-negative EBNA1. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.
[26] E. Flemington,et al. siRNAs against the Epstein Barr virus latency replication factor, EBNA1, inhibit its function and growth of EBV-dependent tumor cells. , 2006, Virology.
[27] Andrew J Davison,et al. Topics in herpesvirus genomics and evolution. , 2006, Virus research.
[28] T. Shenk,et al. Human Cytomegalovirus UL38 Protein Blocks Apoptosis , 2007, Journal of Virology.
[29] D. Dittmer,et al. Kaposi-Sarcoma-Associated Herpesvirus , 2008 .
[30] V. Connor,et al. Histone modifications associated with herpes simplex virus type 1 genomes during quiescence and following ICP0-mediated de-repression , 2008, The Journal of general virology.
[31] E. Clercq,et al. Viral DNA Polymerase Inhibitors , 2009 .
[32] Andrew Rambaut,et al. Evolutionary analysis of the dynamics of viral infectious disease , 2009, Nature Reviews Genetics.
[33] C. Cameron,et al. Viral genome replication , 2009 .
[34] Gonçalo R. Abecasis,et al. The Sequence Alignment/Map format and SAMtools , 2009, Bioinform..
[35] R. Barrangou,et al. CRISPR/Cas, the Immune System of Bacteria and Archaea , 2010, Science.
[36] Kristen D Yetming,et al. UL84-independent replication of human cytomegalovirus strain TB40/E. , 2010, Virology.
[37] N. DeLuca,et al. Activities of ICP0 Involved in the Reversal of Silencing of Quiescent Herpes Simplex Virus 1 , 2011, Journal of Virology.
[38] E. Kieff,et al. Roscovitine Inhibits EBNA1 Serine 393 Phosphorylation, Nuclear Localization, Transcription, and Episome Maintenance , 2011, Journal of Virology.
[39] M. Nicoll,et al. The molecular basis of herpes simplex virus latency , 2012, FEMS microbiology reviews.
[40] Steven L Salzberg,et al. Fast gapped-read alignment with Bowtie 2 , 2012, Nature Methods.
[41] J. Doudna,et al. A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity , 2012, Science.
[42] J. Doudna,et al. RNA-guided genetic silencing systems in bacteria and archaea , 2012, Nature.
[43] Rudolf Jaenisch,et al. One-Step Generation of Mice Carrying Mutations in Multiple Genes by CRISPR/Cas-Mediated Genome Engineering , 2013, Cell.
[44] Yongxiang Zhao,et al. Heritable gene targeting in the mouse and rat using a CRISPR-Cas system , 2013, Nature Biotechnology.
[45] R. Jaenisch,et al. One-Step Generation of Mice Carrying Reporter and Conditional Alleles by CRISPR/Cas-Mediated Genome Engineering , 2013, Cell.
[46] Paul D. Shaw,et al. Using Tablet for visual exploration of second-generation sequencing data , 2013, Briefings Bioinform..
[47] Le Cong,et al. Multiplex Genome Engineering Using CRISPR/Cas Systems , 2013, Science.
[48] Yoshio Koyanagi,et al. Harnessing the CRISPR/Cas9 system to disrupt latent HIV-1 provirus , 2013, Scientific Reports.
[49] S. Y. Kim,et al. Characterization of naturally Epstein-Barr virus-infected gastric carcinoma cell line YCCEL1. , 2013, The Journal of general virology.
[50] G. Church,et al. Cas9 as a versatile tool for engineering biology , 2013, Nature Methods.
[51] T. Flotte. Birth of a new therapeutic platform: 47 years of adeno-associated virus biology from virus discovery to licensed gene therapy. , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.
[52] James E. DiCarlo,et al. RNA-Guided Human Genome Engineering via Cas9 , 2013, Science.
[53] David A. Scott,et al. Double Nicking by RNA-Guided CRISPR Cas9 for Enhanced Genome Editing Specificity , 2013, Cell.
[54] J. Keith Joung,et al. High frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells , 2013, Nature Biotechnology.
[55] Geoffrey M. Hill,et al. Herpes simplex keratitis. , 2014, Disease-a-month : DM.
[56] R. Cohrs,et al. Varicella Zoster Virus , 2014 .
[57] Mazhar Adli,et al. Genome-wide analysis reveals characteristics of off-target sites bound by the Cas9 endonuclease , 2014, Nature Biotechnology.
[58] G. Gao,et al. State-of-the-art human gene therapy: part II. Gene therapy strategies and clinical applications. , 2014, Discovery medicine.
[59] V. Barbaro,et al. Gene transfer of integration defective anti-HSV-1 meganuclease to human corneas ex vivo , 2014, Gene Therapy.
[60] S. Schaffert,et al. Precise gene deletion and replacement using the CRISPR/Cas9 system in human cells. , 2014, BioTechniques.
[61] G. Gao,et al. State-of-the-art human gene therapy: part I. Gene delivery technologies. , 2014, Discovery medicine.
[62] E. Kieff,et al. Small molecule inhibition of Epstein-Barr virus nuclear antigen-1 DNA binding activity interferes with replication and persistence of the viral genome. , 2014, Antiviral research.
[63] J. Keith Joung,et al. Improving CRISPR-Cas nuclease specificity using truncated guide RNAs , 2014, Nature Biotechnology.
[64] S. Quake,et al. RNA-guided endonuclease provides a therapeutic strategy to cure latent herpesviridae infection , 2014, Proceedings of the National Academy of Sciences.
[65] Michael T. McManus,et al. A high-coverage shRNA screen identifies TMEM129 as an E3 ligase involved in ER-associated protein degradation , 2014, Nature Communications.
[66] David Bryder,et al. Efficient ablation of genes in human hematopoietic stem and effector cells using CRISPR/Cas9. , 2014, Cell stem cell.
[67] T. Suenaga,et al. Engineering large viral DNA genomes using the CRISPR‐Cas9 system , 2014, Microbiology and immunology.
[68] Qihan Li,et al. High-Efficiency Targeted Editing of Large Viral Genomes by RNA-Guided Nucleases , 2014, PLoS pathogens.
[69] David A. Scott,et al. Genome-wide binding of the CRISPR endonuclease Cas9 in mammalian cells , 2014, Nature Biotechnology.
[70] G. Boivin,et al. Antiviral drug resistance in herpesviruses other than cytomegalovirus , 2014, Reviews in medical virology.
[71] Meagan E. Sullender,et al. Rational design of highly active sgRNAs for CRISPR-Cas9–mediated gene inactivation , 2014, Nature Biotechnology.
[72] Yoshimitsu Takahashi,et al. In vitro and in vivo growth suppression of human papillomavirus 16-positive cervical cancer cells by CRISPR/Cas9. , 2014, Biochemical and biophysical research communications.
[73] A. Scharenberg,et al. In vitro Inactivation of Latent HSV by Targeted Mutagenesis Using an HSV-specific Homing Endonuclease , 2014, Molecular therapy. Nucleic acids.
[74] Bryan R. Cullen,et al. Inactivation of the Human Papillomavirus E6 or E7 Gene in Cervical Carcinoma Cells by Using a Bacterial CRISPR/Cas RNA-Guided Endonuclease , 2014, Journal of Virology.
[75] E. Lander,et al. Development and Applications of CRISPR-Cas9 for Genome Engineering , 2014, Cell.
[76] M. Luftig,et al. Dynamic Epstein-Barr virus gene expression on the path to B-cell transformation. , 2014, Advances in virus research.
[77] Fan Yang,et al. RNA-directed gene editing specifically eradicates latent and prevents new HIV-1 infection , 2014, Proceedings of the National Academy of Sciences.
[78] B. Cullen,et al. Suppression of hepatitis B virus DNA accumulation in chronically infected cells using a bacterial CRISPR/Cas RNA-guided DNA endonuclease. , 2015, Virology.
[79] Hans Clevers,et al. Efficient Intracellular Delivery of Native Proteins , 2015, Cell.
[80] K. Khalili,et al. CRISPR/Cas9 System as an Agent for Eliminating Polyomavirus JC Infection , 2015, PloS one.
[81] J. Englund,et al. Cytomegalovirus in immunocompromised children , 2015, Current opinion in infectious diseases.
[82] David S. Weiss,et al. Cas9-mediated targeting of viral RNA in eukaryotic cells , 2015, Proceedings of the National Academy of Sciences.
[83] D. Tscharke,et al. Engineering herpes simplex viruses by infection-transfection methods including recombination site targeting by CRISPR/Cas9 nucleases. , 2015, Journal of virological methods.
[84] Martin J. Aryee,et al. Engineered CRISPR-Cas9 nucleases with altered PAM specificities , 2015, Nature.
[85] J. Doudna,et al. Expanding the Biologist's Toolkit with CRISPR-Cas9. , 2015, Molecular cell.
[86] J. Keith Joung,et al. Efficient Delivery of Genome-Editing Proteins In Vitro and In Vivo , 2014, Nature Biotechnology.
[87] Keiichiro Suzuki,et al. Use of the CRISPR/Cas9 system as an intracellular defense against HIV-1 infection in human cells , 2015, Nature Communications.
[88] Won-Bin Young,et al. CRISPR/gRNA-directed synergistic activation mediator (SAM) induces specific, persistent and robust reactivation of the HIV-1 latent reservoirs , 2015, Scientific Reports.
[89] Honglin Chen,et al. CRISPR/Cas9-mediated genome editing of Epstein-Barr virus in human cells. , 2015, The Journal of general virology.
[90] David A. Scott,et al. Rationally engineered Cas9 nucleases with improved specificity , 2015, Science.
[91] J. Joung,et al. High-fidelity CRISPR-Cas9 variants with undetectable genome-wide off-targets , 2015, Nature.
[92] J. Karn,et al. Elimination of HIV-1 Genomes from Human T-lymphoid Cells by CRISPR / Cas 9 Gene Editing SUPPLEMENTARY MATERIALS , 2016 .
[93] J. Keith Joung,et al. 731. High-Fidelity CRISPR-Cas9 Nucleases with No Detectable Genome-Wide Off-Target Effects , 2016 .
[94] Derrick J Chen,et al. Epstein-Barr Virus , 2016, Succinct Pediatrics: Evaluation and Management of Infectious Diseases and Dermatology.